Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A ready-to-use cancer vaccine for leukemia is gaining momentum. Evaxion's EVX-04, an AI-designed therapeutic vaccine for acute myeloid leukemia (AML), has demonstrated broad patient coverage, consistent target expression across disease stages, and immune responses in preclinical models. New validation data will be presented at the ASH 2026 Annual Meeting in December.
A ready-to-use cancer vaccine for leukemia is gaining momentum. Evaxion's EVX-04 is an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), developed using the company's AI-Immunology™ platform. New data set to be presented at the American Society of Hematology (ASH) Annual Meeting in December 2026 show that EVX-04 demonstrates broad patient coverage, conserved target expression across disease stages, and the ability to trigger ERV-specific T-cell responses in humanized mice — building on earlier preclinical findings of tumor growth inhibition.
EVX-04 works by targeting endogenous retrovirus (ERV) antigens — fragments from the so-called "dark genome" that are expressed in tumor cells but absent in normal tissue. Evaxion's AI platform sifted through five million ERV antigen fragments to identify 16 optimal sets, each capable of eliciting an immune response and preventing tumor growth in preclinical models.
By the Numbers:
Why it matters: AML is the most common leukemia and disproportionately affects older adults, many of whom can't tolerate aggressive treatment. An off-the-shelf vaccine that's ready to administer at diagnosis — without needing personalization — could be a game-changer for this underserved population.
